iNO

Phase 1Small molecule

UUniversity of Colorado, Denver

iNO is one of 85 small molecule programs targeting Pulmonary Hypertension. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary HypertensionActive, not recruiting

Nitric OxideCompleted

Ischemic StrokeRecruiting

Pulmonary HypertensionPreclinical

Active, not recruiting

Nitric OxidePreclinical

Completed

Ischemic StrokePhase 1

Recruiting

Competition

Competitive Landscape

119 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Reminyl

WWim Janssens

Phase 3

1 2

Intravenous Thrombolysis

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3

6 3

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 4

PCSK9 Inhibitor

YYun Dai Chen

Phase 3

3 5

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

1 6

Aggrastat

MMedicure

Phase 3

4 7

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Phase 3

10 8

Tenecteplase or Alteplase

IInsel Gruppe AG, University Hospital Bern

Phase 3

2 9

Proamatine

Takeda

Preclinical

2 10

Levaquin

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Ischemic Stroke

NCT05871606

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy

Recruiting·WWake Forest University Health Sciences·Phase 1·NCT05871606·36 enrolled

Pulmonary Hypertension1 trial

NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn

Completed·EEmory University·N/A·NCT00139217·400 enrolled

Nitric Oxide1 trial

Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation

Completed·UUniversity of Oklahoma·N/A·NCT01220687·33 enrolled

Lung Transplantation1 trial

Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes

Completed·—·Phase 4·NCT03081052·519 enrolled

Tolerance1 trial

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

Withdrawn·BBellerophon Pulse Technologies·Phase 3·NCT03602781

1 more indication

Chronic Lung Disease1 trial

Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants

Completed·UUniversity of Colorado, Denver·Phase 3·NCT00006401·793 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for iNO. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iNO compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iNO. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Denver company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Colorado, Denver

iNO

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Ischemic stroke1 trial

Pulmonary Hypertension1 trial

Nitric Oxide1 trial

Lung Transplantation1 trial

Tolerance1 trial

Chronic Lung Disease1 trial

References

Drug Info

Quick Facts

Related News